Journal of managed care & specialty pharmacy
-
J Manag Care Spec Pharm · Dec 2018
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
The recent approval of olaparib and niraparib as maintenance therapy can significantly affect the management of ovarian cancer. Clinical benefits, however, come with trade-offs in adverse events and costs. ⋯ This study was unfunded. The authors have nothing to disclose.